10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

[Mark One]

☒  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2018

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____to______

Commission file number: 000-26028

IMAGING DIAGNOSTIC SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Florida	22-2671269
(State of Incorporation)	(IRS Employer Identification No.)

1291-B  NW 65th Place, Fort Lauderdale, FL	33309
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number: (954) 581-9800

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer       ☐	Accelerated filer       ☐	Smaller reporting company       ☒
Non-accelerated filer         ☐	(Do not check if a smaller reporting company)	Emerging growth company       ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)

Yes ☐ No ☒

The number of shares outstanding of the issuer’s common stock as of November 9, 2018: 120,641,250 shares of common stock, no par value.

Explanatory Note

Imaging Diagnostic Systems, Inc. (the “Company”, “we” or “our”) is filing this amendment to our Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2018, originally filed on February 14, 2019 (the “Original Filing”), to furnish Exhibit 101 to the Form 10-Q, which provides certain items from the Original Filing formatted in eXtensible Business Reporting Language (“XBRL”).

The remainder of the Original Filing, including the condensed financial statements, remains unchanged. This Form 10-Q/A should be read in conjunction with the Original Filing which continues to speak as of the date of the Original Filing, and does not modify or update disclosures in the Original Filing, except as noted above. This Form 10-Q/A does not reflect events occurring after the filing of the Original Filing.

PART II – OTHER INFORMATION

Item 6. Exhibits

31.1*	Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**	XBRL Instance Document
101.SCH**	XBRL Taxonomy Extension Schema Document
101.CAL**	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**	XBRL Taxonomy Extension Label Linkbase Document
101.PRE**	XBRL Taxonomy Extension Presentation Linkbase Document

*

Previously filed as an exhibit to the Form 10-Q.

**

In accordance with Rule 402 of Regulation S-T, the information in these exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing

1

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated March 5, 2019	Imaging Diagnostic Systems, Inc.
	By:	/s/ David Fong
		David Fong Chief Financial Officer

2

XML

Document and Entity Information - shares	6 Months Ended
	Dec. 31, 2018	Feb. 14, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	IMAGING DIAGNOSTIC SYSTEMS INC /FL/
Entity Central Index Key	0000790652
Trading Symbol	IMDS
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Type	10-Q
Document Period End Date	Dec. 31, 2018
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		121,935,372

XML

Balance Sheets - USD ($)	Dec. 31, 2018	Jun. 30, 2018
Current assets:
Cash	$ 15,905	$ 271,540
Due from related party	134,018	34,853
Royalty receivable		21,753
Other receivable	11,965	850
Prepaid expenses	22,212	22,750
Total current assets	184,100	351,746
Property and equipment, net	23,285	27,178
Total assets	207,385	378,924
Current liabilities:
Accounts payable and accrued expenses	56,330	69,756
Accrued payroll taxes and penalties	314,020	314,019
Short term debt	400,000
Convertible Preferred Series L	370,988	361,914
Total current liabilities	1,141,338	745,689
Total liabilities	1,141,338	745,689
Commitment and Contingencies (Note 15)
Stockholders' (Deficit):
Preferred stock, no par , 2,000,000 authorized Convertible preferred stock, Series M, 600 designated 0 and 591 shares issued and outstanding at December 31, 2018 and June 30, 2018, respectively		7,589,173
Common stock, no par value, 500,000,000 authorized , 120,935,373 and 33,597,241 shares issued and outstanding at December 31, 2018 and June 30, 2018, respectively	124,112,797	118,052,797
Additional paid-in capital	7,055,382	7,055,382
Subscription Deposits	50,000
Accumulated Deficit	(132,152,132)	(133,064,117)
Total stockholders' (Deficit)	(933,953)	(366,765)
Total liabilities and stockholders' (Deficit)	$ 207,385	$ 378,924

XML

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Jun. 30, 2018
Preferred Stock, par value
Preferred Stock, shares authorized	2,000,000	2,000,000
Common Stock, par value
Common Stock, shares authorized	500,000,000	500,000,000
Common Stock, shares issued	120,935,373	33,597,241
Common Stock, shares outstanding	120,935,373	33,597,241
Series M Preferred stock [Member]
Preferred stock, designated	600	600
Preferred Stock, shares issued	0	591
Preferred Stock, shares outstanding	0	591

XML

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Sales, related party	$ 11,278		$ 149,066	$ 15,158
Royalty Revenue		83,506		83,506
Service revenue				5,375
Total Revenue	11,278	83,506	149,066	104,039
Cost of Sales	1,308		64,734	215
Gross Profit	9,970	83,506	84,332	103,824
Operating Expenses:
General and administrative	227,849	249,601	522,668	466,635
Salaries and wages	140,196	146,863	280,526	303,765
Research and development	17,413	4,477	52,069	22,884
Sales and marketing	(6,301)	5,130	(5,794)	14,292
Depreciation and amortization	1,947	1,947	3,893	3,893
Total Operating Expenses	381,104	408,018	853,362	811,469
Operating Loss	(371,134)	(324,512)	(769,030)	(707,645)
Other Income (expense)
Interest income	7		22	3
Other Income	27,837	16,301	27,867	24,232
Interest expense	(13,685)	(44,594)	(16,973)	(88,548)
Total Other Income (Expense)	14,159	(28,293)	10,916	(64,313)
Net Loss	(356,975)	(352,805)	(758,114)	(771,958)
Preferred Stock Dividends	(4,537)	(139,285)	(9,074)	(278,571)
Net Loss Available to Common Stockholders'	$ (361,512)	$ (492,090)	$ (767,188)	$ (1,050,529)
Net Loss per common share:
Basic and diluted		$ (0.02)	$ (0.01)	$ (0.05)
Weighted average number of common shares outstanding:
Basic and diluted	120,654,044	22,222,373	102,671,166	21,998,442

XML

Statements of Changes in Stockholders’ (Deficit) (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Subscription Deposits	Accumulated Deficit	Total
Beginning balance at Jun. 30, 2018	$ 7,589,173	$ 118,052,797	$ 7,055,382		$ (133,064,117)	$ (366,765)
Beginning balance, shares at Jun. 30, 2018	591	33,597,241
Conversion Viable Series M Cv Preferred to common stock	$ (5,910,000)	$ 5,910,000
Conversion Viable Series M Cv Preferred to common stock, shares	(591)	87,044,089
Cummulative Dividend on Series M CV Preferred	$ (1,679,173)				1,679,173
Cummulative Dividend on Series L CV Preferred					(4,537)	(4,537)
Adjustment to correct number of common shares
Adjustment to correct number of common shares, shares		(80)
Net loss					(401,142)	(401,142)
Ending balance at Sep. 30, 2018		$ 123,962,797	7,055,382		(131,790,623)	(772,444)
Ending balance, shares at Sep. 30, 2018		120,641,250
Beginning balance at Jun. 30, 2018	$ 7,589,173	$ 118,052,797	7,055,382		(133,064,117)	(366,765)
Beginning balance, shares at Jun. 30, 2018	591	33,597,241
Net loss						(758,114)
Ending balance at Dec. 31, 2018		$ 124,112,797	7,055,382	50,000	(132,152,132)	(933,953)
Ending balance, shares at Dec. 31, 2018		120,935,373
Beginning balance at Sep. 30, 2018		$ 123,962,797	7,055,382		(131,790,623)	(772,444)
Beginning balance, shares at Sep. 30, 2018		120,641,250
Cummulative Dividend on Series L CV Preferred					(4,537)	(4,537)
Adjustment to correct number of common shares
Adjustment to correct number of common shares, shares		6
Shares Issued		$ 150,000				150,000
Shares Issued, shares		294,117
Subscription Deposit Received				50,000		50,000
Net loss					(356,972)	(356,975)
Ending balance at Dec. 31, 2018		$ 124,112,797	$ 7,055,382	$ 50,000	$ (132,152,132)	$ (933,953)
Ending balance, shares at Dec. 31, 2018		120,935,373

XML

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement of Cash Flows [Abstract]
Net loss	$ (758,114)	$ (771,958)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,893	3,893
Changes in assets and liabilities:
(Increase) decrease in due from related party	(99,165)	(40,158)
(Increase) decrease in royalty receivable	21,753	(83,506)
(Increase) decrease in other receivables	(11,115)
(Increase) decrease in prepaid expenses	538	(667)
Increase (decrease) in accounts payable and accrued expenses	(13,426)	246,608
Increase (decrease) in accrued payroll taxes and penalties	1	(20,000)
Total adjustments	(97,521)	106,171
Net cash used in operating activities	(855,635)	(665,787)
Cash flows from investing activities:
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from loan payable	400,000
(Repayment) of loan payable		(78,500)
Proceeds from common stock subscription deposits	50,000	248,000
Proceeds from issuance of common stocks	150,000	300,000
Net cash provided by financing activities	600,000	469,500
Net decrease in cash and cash equivalents	(255,635)	(196,287)
Cash and cash equivalents at beginning of period	271,540	199,044
Cash and cash equivalents at end of period	15,905	2,757
Supplemental Disclosure of cash flow information:
Cash paid during the year for interest	12,822
Cash paid during the year for taxes

XML

Organization and Nature of Business

6 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND NATURE OF BUSINESS

(1) ORGANIZATION AND NATURE OF BUSINESS

Imaging Diagnostic Systems, Inc. (“the Company” or “IDSI”) is a medical technology company that has developed a new, non-invasive CT scanner called CTLM® that uses a laser beam in place of ionizing X-ray for breast imaging. This technology is called Diffuse Optical Tomography. The CTLM® will provide an adjunctive imaging modality to other methods of imaging the breast such as X-ray mammography, MRI and ultrasound.

XML

Going Concern and Management's Plans

6 Months Ended

Dec. 31, 2018

Going Concern and Management's Plans [Abstract]

GOING CONCERN AND MANAGEMENT'S PLANS

(2) GOING CONCERN AND MANAGEMENT'S PLANS

The accompanying financial statements are prepared assuming the Company will continue as a going concern. As of December 31, 2018, the Company had an accumulated deficit of $132,152,132, a stockholders' deficit of $933,953, and a working capital deficiency of $957,236. For the six months ended December 31, 2018, net loss totaled $758,114. The net cash used in operating activities for the six months ended December 31, 2018 totaled $855,635. These matters raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements are issued. The ability of the Company to continue as a going concern is dependent upon increasing sales and obtaining additional capital and financing. While the Company believes in the viability of its strategy to increase sales volume and in its ability to raise additional funds, there can be no assurances to that effect. The Company received China marketing clearance for the CTLM® (CFDA approval) effective November 16, 2018 to November 15, 2023 as disclosed in the Company's 8-K filing on December 11, 2018. However, there can be no assurance that we will obtain US FDA marketing or other new international marketing clearances, that the CTLM® will achieve market acceptance in China or elsewhere or that sufficient revenues will be generated from sales of the CTLM® to allow us to operate profitably. If our majority shareholder Viable International Investments, LLC ("Viable") fails to continue funding, the Company would be materially adversely affected and may have to cease operations due to a lack of funding. These matters affect the Company's liquidity profile, and management's plans in those regards are discussed in the paragraphs that follow.

For the remainder of fiscal year 2019, we anticipate that losses from operations will continue until we begin to generate revenues through the sales of CTLM® systems in China. These losses will be primarily due to an anticipated increase in marketing, manufacturing and operational expenses associated with the international commercialization of the CTLM®, expenses associated with US FDA approval processes, and the costs associated with advanced product development activities.

The Company's next focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of the CTLM® through the US FDA. The PMA process for U.S. marketing clearance is expected to take much longer than the Chinese process. Sales in China are expected to commence in the second half of fiscal 2019. No sales in the U.S. are expected in fiscal 2019 or fiscal 2020. The Company has received the CE Mark which would allow it to sell its CTLM® System in the European Union and other countries that recognize the CE Mark; however, the Company does not expect material sales in Europe until it receives U.S. marketing clearance.

The Company's ability to continue as a going concern and its future success is dependent upon its ability to raise additional capital in the near term to: (1) satisfy its current obligations, (2) continue its research and development efforts, and (3) successfully develop, market, and sell its products. The Company believes that it will be able to complete the necessary steps in order to meet its cash flow requirements throughout fiscal 2019 and continue its development and commercialization efforts. However, there can be no assurance that IDSI will generate sufficient revenue to provide positive cash flows from operations or that sufficient capital will be available, when required, to permit the Company to realize its plans. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML

Summary of Significant Accounting Policies

6 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of presentation and use of estimates

The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America ("U.S. GAAP"). The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.

These unaudited financial statements should be read in conjunction with the Company's audited financial statements for the year ended June 30, 2018, contained in our General Form for Registration of Securities of Form 10 as filed with the Securities and Exchange Commission (the "Commission") on August 28, 2018, as amended on October 5, 2018, and as amended on November 14, 2018. The results of operations for the six months ended December 31, 2018, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2019.

(b) Revenue recognition

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) ("ASC 606"). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue.

(c) Allowance for doubtful accounts

In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.

Our allowance for doubtful accounts was $-0- as of December 31, 2018 and June 30, 2018.

(d) Cash and cash equivalents

Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at December 31, 2018 and June 30, 2018.

(e) Concentration of Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.

The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company's cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. At December 31, 2018 and June 30, 2018, the Company had $0 and $0 in excess of the federally insured limit.

For the six months ended December 31, 2018 and December 31, 2017, the Company had the following 10 percent or greater concentrations of revenue with its customers:

	December 31, 2018			December 31, 2017
Xi'an IDI Laser Image		100	%		15	%
Trifoil		0	%		80	%
All other		0	%		5	%
Total		100	%		100	%

(f) Inventory

Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of slow moving or obsolete inventory. The Company maintains a reserve for obsolete inventory and generally makes inventory value adjustments against the reserve.

(g) Property and equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.

(h) Research and development

Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company's CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.

(i) Net loss per share

The Company relies on the guidance provided by ASC 260, ("Earnings per Share"), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.

The Company had 4,811,610 and 4,811,610 options vested as of December 31, 2018 and June 30, 2018, respectively.

(j) Stock-based compensation

The Company relies on the guidance provided by ASC 718, ("Share Based Payments"). ASC 718 requires companies to expense the value of employee stock options and similar awards and applies to all outstanding and vested stock-based awards.

In computing the impact, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company's stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company's forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company's actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. For the six months ended December 31, 2018 and 2017, no stock options were granted to employees and consultants. Stock options are being expensed pursuant to ASC 718.

The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite service period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See (14) Stock Options.

(k) Long-lived assets

The Company relies on the guidance provided by ASC 360 ("Property, Plant & Equipment"). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.

The Company has determined that no impairment losses need to be recognized through the six months ended December 31, 2018 and 2017.

(l) Income taxes

The Company accounts for income taxes pursuant to the provisions of ASC 740-10, "Accounting for Income Taxes," which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.

Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions.

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2015-2018 are still potentially subject to audit by the taxing authorities.

(m) Warranty reserve

The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products was/were shipped from IDSI, whichever occurs first. The table below reflects the warranty reserve established for the six months ended December 31, 2018 and the fiscal year ended June 30, 2018. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company's experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company's estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The following warranty reserve balances are included in accounts payable and accrued expenses.

	December 31, 2018		June 30, 2018
Warranty reserve	$	0	$	6,411

(n) Impact of recently issued accounting pronouncements

In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02"). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its financial statements.

In June 2018, the FASB issued ASU No. 2018-07, "Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting." ASU 2018-07 aligns accounting for share-based payments issued to nonemployees to that of employees under the existing guidance of Topic 718, with certain exceptions. This update supersedes previous guidance for equity-based payments to nonemployees under Subtopic 505-50, "Equity – Equity-based Payments to Nonemployees." It is effective for annual reporting periods beginning after December 15, 2018. The Company is currently evaluating the impact the adoption of this new standard will have on its financial statements.

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.

(o) Fair Value of Financial Instruments

The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company's debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At December 31, 2018 and June 30, 2018, the aggregate fair value of the Company's debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 ("Fair Value Measurements and Disclosures"). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:

Level 1 - Quoted prices in active markets for identical assets or liabilities

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

XML

Revenue

6 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

REVENUE

(4) REVENUE

The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Sales taxes and other similar taxes are excluded from revenue.

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) ("ASC 606"). The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The Company adopted the standard using the modified retrospective method and the adoption did not have a material impact on its financial statements. The Company expects that the impact to net income of the new standard will be immaterial on an ongoing quarterly and annual basis. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.

Information about the Company's net sales by reporting segment for the six months ended December 31, 2018 and 2017 is as follows:

	For the six months ended
	December 31,		December 31,
	2018		2017
Sales-parts	$	149,066	$	15,158
Royalty Revenue		-		83,506
Service revenue		-		5,375
Net sales	$	149,066	$	104,039

XML

Due from Related Party

6 Months Ended

Dec. 31, 2018

Related Party Transactions [Abstract]

DUE FROM RELATED PARTY

(5) DUE FROM RELATED PARTY

On March 22, 2018, the Board of Directors approved the execution of two agreements with Xi'an IDI Laser Image Ltd. ("Xi'an") of China, an affiliated company of IDSI. The agreements are a Know How Transfer Contract and a CTLM Know How Confidentiality Agreement. The contract, having a term of 20 years, stipulates that Xi'an will pay IDSI a know how transfer fee of 25% of revenue for CTLM product sales in their territory, which includes China, Hong Kong, Macau and Taiwan. The Company also sells inventory parts or acquires parts from third parties on behalf of Xi'an. For the six months ended December 31, 2018 and 2017, such sales totaled $149,066 and $15,158, respectively. As of December 31, 2018 and June 30, 2018, the Company has receivables from related parties of $134,018 and $34,853, respectively as a result of sales of inventory parts or acquisition of parts from third parties on behalf of Xi'an. Xi'an and Viable have common ownership hence these transactions are considered related party transactions.

XML

Royalty Receivable

6 Months Ended

Dec. 31, 2018

Royalty Receivable [Abstract]

ROYALTY RECEIVABLE

(6) ROYALTY RECEIVABLE

On June 16, 2006, the Company entered into a Royalty Agreement with Bioscan Inc. whereby the Company established a licensing relationship with Bioscan which granted Bioscan an exclusive sublicensable, royalty-bearing license to make, use, offer for sale, import and otherwise develop and commercialize products in its territory. Bioscan Inc. was subsequently purchased by TriFoil Imaging. During the six months ended December 31, 2018, there was no royalty income.

XML

Inventories

6 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

INVENTORIES

(7) INVENTORIES

Inventories consisted of the following:

	December 31,			June 30,
	2018			2018
Raw materials consisting of purchased parts, components and supplies	$	386,588		$	415,262
Work-in process including units undergoing final inspection and testing		52,500			52,500
Finished goods		15,000			15,000
Total Inventory	$	454,088		$	482,762
Inventory Reserve		(454,088	)		(482,762	)
Net Inventory	$	-		$	-

Due to the age of the inventory, lack of demand for parts and lack of sales the Company has booked a reserve for the entire value of its inventory as of June 30, 2018. For the six months ended December 31, 2018, reduction of inventory represents items that were sold from inventory held. In addition, the Company purchased approximately $65,000 of inventory parts which was recorded as cost of sales. The Company sold those parts to Xi'an (see note 5).

XML

Property and Equipment

6 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

(8) PROPERTY AND EQUIPMENT

The following is a summary of property and equipment, less accumulated depreciation:

	December 31, 2018			June 30, 2018			Useful life
Furniture and Fixtures	$	261,011		$	261,011		5 years
Computers and Equipment		370,704			370,704		5 years
Third Party Software		10,291			10,291		5 years
Clinical Equipment		15,000			15,000		5 years
Total Property & Equipment	$	657,006		$	657,006
Less: accumulated depreciation		(633,723	)		(629,828	)
Total Property & Equipment - Net	$	23,283		$	27,178

Depreciation expense for the six months December 31, 2018 and 2017 was $3,893 and $3,893 respectively.

XML

Accounts Payable and Accrued Expenses

6 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

(9) ACCOUNTS PAYABLE AND ACCRUED EXPENSES

As of December 31, 2018, and June 30, 2018, accounts payable and accrued expenses totaled $56,330 and $69,756 of which consists of accounts payable of $25,065 and $2,308, warranty reserve of $0 and $6,411, and other accrued expenses of $30,265 and $61,037, respectively. During the year ended June 30, 2018 the Company settled various accounts payable and accrued expenses with vendors or wrote-off old accounts payables due to the expiration of the statute of limitation resulting in write-offs of accounts payable and accrued expenses of $44,611. During the year ended June 30, 2018, the Company issued restricted common shares for settlement of $20,000 of accrued salaries and $190,000 of accounts payable.

XML

Accrued Payroll Taxes and Penalties

6 Months Ended

Dec. 31, 2018

Payables and Accruals [Abstract]

ACCRUED PAYROLL TAXES AND PENALTIES

(10) ACCRUED PAYROLL TAXES AND PENALTIES

As of December 31, 2018, and June 30, 2018, the Company owes the IRS $314,020 and $314,019, respectively, with the difference due to a rounding adjustment. The Company under previous management accrued substantial unfunded payroll taxes, interest and penalties commencing with the quarter ending March 31, 2010. As part of new management's restructuring plan, the Company received funds from an affiliated accredited investor to be able to make a payment to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC ("Viable") provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting penalties and interest abatement. The amount due at December 31, 2018 of $314,018 represents the interest and penalty. The Company has formally asked the IRS to abate all remaining interest and penalties of $314,018.

XML

Short-Term Debt-Related Parties

6 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

SHORT-TERM DEBT-RELATED PARTIES

(11) SHORT-TERM DEBT-RELATED PARTIES

The following table is a summary of the outstanding note balance as of December 31, 2018 and June 30, 2018.

Noteholder	Interest Rate			Maturity Date	December 31, 2018		June 30, 2018
Related parties debt:
Erhfort, LLC		15	%	8/8/2019	$	100,000	$	-0-
Erhfort, LLC		15	%	9/12/2019		100,000		-0-
Erhfort, LLC		15	%	10/24/2019		50,000		-0-
Erhfort, LLC		15	%	11/15/2019		50,000		-0-
Qing Wang		15	%	9/21/2019		100,000		-0-
Total Related Party Debt					$	400,000	$	-0-

Erhfort, LLC and Qing Wang both own common stock in the Company and hence are considered related parties. During the year ended June 30, 2018, the Company issued 1,000,000 restricted common shares to Viable as settlement of $200,000 of debt. On April 27, 2018, the Company paid Redwood Management $63,500 as settlement of debt plus a $1,000 late payment fee.

XML

Convertible Preferred Stock

6 Months Ended

Dec. 31, 2018

Equity [Abstract]

CONVERTIBLE PREFERRED STOCK

(12) CONVERTIBLE PREFERRED STOCK

The following schedule reflects the number of shares of preferred stock that have been issued, converted and are outstanding as of December 31, 2018:

Security	Date Issued	No. of Shares	Amount		Date of Conversion	No. of Shares Converted	Amount Converted		Balance 09/30/2018
Series M Cv Pfd	8/1/2014	250	$	2,500,000	4/18/2017	6	$	60,000
					11/21/2017	3		30,000
					8/7/2018	241		2,410,000	$	-0-
Series M Cv Pfd	8/31/2015	200		2,000,000	8/7/2018	200		2,000,000		-0-
Series M Cv Pfd	4/22/2016	150		1,500,000	8/7/2018	150		1,500,000		-0-
Total		600	$	6,000,000			$	6,000,000	$	-0-
Accrued Dividends										-0-
									$	-0-
Series L Cv Pfd	2/10/2010	35	$	350,000	1/6/2011	15	$	150,000	$	200,000
Accrued Dividends										170,988
									$	370,988

Series L Convertible Preferred Stock

On March 31, 2010, a private investor converted a $350,000 short-term promissory note into 35 shares of Series L Convertible Preferred Stock. The original purchase price/stated value is $10,000 per share and dividends accrue at an annual rate of 9%. The preferred stock is convertible into 474 shares of common stock for each share of preferred stock. On January 6, 2011, the private investor converted 15 shares of Series L Convertible Preferred Stock representing a principal value of $150,000. After the conversion, the private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as a current liability since it is mandatorily redeemable. At December 31, 2018 and June 30, 2018, the balance of cumulative dividends owed to the investor which is included in redemption value was $170,988 and $161,914, respectively. The remaining principal value of $200,000 plus the cumulative dividend are presented on the balance sheet as a current liability of $370,988 as of December 31, 2018 and $361,914 as of June 30, 2018.

Series M Convertible Preferred Stock

The Company, during the fiscal year ending June 30, 2015, sold Series M Convertible Preferred Stock to Viable International Investments, LLC, a Florida limited liability company, (“Viable”). The original purchase price/stated value of each share of Series M Preferred Stock was $10,000 and Viable was be entitled to receive cumulative dividends at the fixed rate of 9% of the stated value per share per annum. The first tranche of the private placement sale of 250 shares of convertible preferred stock was made pursuant to a Securities Purchase Agreement (the “Agreement”) dated June 27, 2014 between the Company and Viable. The Agreement stipulated the payment of a $100,000 non-refundable deposit which was paid on June 27, 2014 and applied to the purchase price on the first closing date, August 4, 2014. At the first closing, $2,400,000 was paid by Viable to purchase 250 shares of convertible preferred stock which provided a 78.9% voting and economic interest in the Company’s capital stock representing a change in control of the Company. Because of delays in restructuring the Company and executing its business plan, Viable was unable to convert its Series M Convertible Preferred Stock into Common Stock according to its timeline. On June 1, 2016, Viable presented the Company with a waiver that permanently waived its rights under Section 3 – Redemption at Holder’s Option of the Certificate of Designations of the Series M Preferred Stock. Therefore, the Company reclassified the Series M Preferred Shares to permanent equity from temporary equity on June 1, 2016.

Viable, at its option, deviated from the stipulated payment schedules and purchased 200 Series M shares for $2,000,000 on August 31, 2015, and 150 Series M shares for $1,500,000 on April 22, 2016, which completed all of the payments required pursuant to the Agreement. The Series M dividends were payable at the Company’s option in cash or common stock. Accordingly, after the reclassification of Series M from temporary equity to permeant equity the Company has continued to accrue the dividend as a charge to retained earnings and a credit to preferred stock Series M in permanent equity. Upon conversion of the remaining 591 Series M shares to common stock on August 7, 2018, the accrued dividends were forfeited and reversed to retained earnings as the Company does not have any further obligations for payment of such accrued dividends. At December 31, 2018 and June 30, 2018, the balance of cumulative dividends owed to the investor which is included in redemption value was $0 and $1,679,173, respectively.

On November 21, 2017, Viable exercised its right to convert three shares of its Series M Convertible Preferred Stock valued at $30,000 into 441,848 shares of restricted common stock. Subsequent to the conversion, Viable sold a total of 392,157 restricted common shares to three accredited investors in China and retained 49,691 restricted common shares for its portfolio. The underlying Series M Convertible Preferred Stock held by Viable was issued with a restrictive legend pursuant to Rule 144 because the shares were not registered. Any conversions to common stock would also be issued with a restrictive legend pursuant to Rule 144.

On April 18, 2017, Viable exercised its right to convert six shares of its Series M Convertible Preferred Stock valued at $60,000 into 883,696 shares of restricted common stock. Subsequent to the conversion, Viable sold a total of 872,787 restricted common shares to three accredited investors in China and retained 10,909 restricted common shares for its portfolio. The underlying Series M Convertible Preferred Stock held by Viable was issued with a

restricted legend pursuant to Rule 144 because the shares were not registered. Any conversions to common stock would also be issued with a restricted legend pursuant to Rule 144.

On August 7, 2018, Viable converted its remaining 591 shares Series M Convertible Preferred Stock into 87,044,089 shares of restricted common stock.

XML

Common Stock

6 Months Ended

Dec. 31, 2018

Equity [Abstract]

COMMON STOCK

(13) COMMON STOCK

On July 12, 2018, the majority shareholder of the Company, Viable International Investments, LLC delivered a written request to effect a one-for-1000 reverse stock split in the form of a Written Consent of the Majority Shareholder of Imaging Diagnostic Systems, Inc. The Board of Directors of the Corporation believed it to be in the best interest of the Corporation and recommended that the stockholders approve a one-for-1000 reverse stock split of the Corporation’s issued and outstanding shares of Common Stock and a decrease in the amount of shares of Common Stock authorized to be issued from 40,000,000,000 shares to 500,000,000 shares. After receiving stockholder approval by majority written consent, the Company filed amended and restated Articles of Incorporation with the Florida Secretary of State on July 12, 2018 to record this action. The reverse stock split became effective July 27, 2018. The Company has retroactively adjusted its financial statements for the effect of the reverse stock split.

The Company has 500,000,000 of common shares no par value authorized and 2,000,000 of no par preferred shares authorized.

During the six months ended December 31, 2018, the Company issued a total of 87,338,207 shares of its common stock.

On August 7, 2018, Viable exercised its right to convert the remaining 591 shares of its Series M Convertible Preferred Stock valued at $5,910,000 into 87,044,089 shares of restricted common stock. The underlying Series M Convertible Preferred Stock held by Viable was issued with a restrictive legend pursuant to Rule 144 because the shares were not registered. Any conversions to common stock would also be issued with a restrictive legend pursuant to Rule 144.

On December 27, 2018, the Company issued 98,039 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $50,000. The price per share was approximately $0.51 per share.

On December 27, 2018, the Company issued 98,039 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $50,000. The price per share was approximately $0.51 per share.

On December 27, 2018, the Company issued 98,039 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $50,000. The price per share was approximately $0.51 per share.

During the year ended June 30, 2018, the Company issued a total of 11,822,730 shares of its common stock.

On November 21, 2017, Viable exercised its right to convert three shares of its Series M Convertible Preferred Stock valued at $30,000 into 441,848 shares of restricted common stock.

The Company issued shares pursuant to subscription agreement as follows:

On November 21, 2017, the Company sold 588,235 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $300,000. The price per share was approximately $0.51 per share.

On April 23, 2018, the Company sold 588,235 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $300,000. The price per share was approximately $0.51 per share.

On May 20, 2018, the Company sold 392,157 shares of restricted common stock to an accredited investor, pursuant to a subscription agreement for $200,000. The shares, priced at $0.51 per share, were issued on June 30, 2018.

On June 28, 2018, the Company sold 1,372,549 shares of restricted common stock to an accredited investor, pursuant to a subscription agreement for $700,000. The shares, priced at $0.51 per share, were issued on June 30, 2018.

The Company issued shares as settlement of Company debt as follows:

On January 10, 2018, the Company issued 1,000,000 restricted common shares as settlement of $200,000 of Company debt. The price per share was $0.20 per share.

On April 23, 2018, the Company issued 1,500,000 restricted common shares as settlement of $300,000 of Company debt. The price per share was $0.20 per share.

On June 28, 2018, the Company issued 3,000,000 restricted common shares as settlement of $600,000 of Company debt. The price per share was $0.20 per share.

On August 15, 2016, an accredited investor, loaned the Company the sum of $750,000 pursuant to a convertible promissory note. Pursuant to a debt to equity agreement dated June 28, 2018, the investor converted the principal of $750,000 and interest of $213,750 into 1,889,706 shares of restricted common stock. The conversion price was $0.51 per share, based on the last cash sale price of the Company’s common stock. The conversion feature per the agreement is based on the public market trading price; however, since the Company is not an active trading company, the most recent cash price was used.

The Company issued shares as settlement of Accounts Payable and Accrued Expenses as follows:

On January 10, 2018, the Company issued 100,000 restricted common shares as settlement of $20,000 accrued salaries. The price per share was $0.20 per share.

On January 10, 2018, the Company issued 240,000 restricted common shares as settlement of $48,000 of accounts payable. The price per share was $0.20 per share.

On April 23, 2018, the Company issued 710,000 restricted common shares as settlement of $142,000 of accounts payable. The price per share was $0.20 per share.

XML

Stock Options

6 Months Ended

Dec. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK OPTIONS

(14) STOCK OPTIONS

On December 4, 2016, the Board of Directors adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”) which was subsequently approved and adopted by majority written consent in lieu of an annual meeting. The purpose of the 2016 Plan is to encourage and enable the officers, employees, directors and other key persons (including consultants) of the Company, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.

On January 1, 2017, the Board granted options to purchase a total of 7,364,136 shares, all with an exercise price of $0.20 per share. Options were granted to nine employees to purchase 5,498,555 shares and to six consultants to purchase 1,865,581 shares. On January 1, 2018, the Board granted options to purchase 5,000,000 shares all with an exercise price of $0.20 per share to four consultants. On May 1, 2018, the Board granted options to purchase 500,000 shares all with an exercise price of $0.20 per share to an additional consultant.

In computing the impact of stock option grants, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payments awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. The Company cannot assess its forfeiture rate at this time. During the six months ended December 31, 2018, the options issued above were valued using the Black-Scholes model but based on exercise price and fair value being the same. Under these assumptions, the options had zero value.

	As of December 31, 2018			As of June 30, 2018
Expected volatility		0.00	%		0.00	%
Expected term		3 Years			3 Years
Risk-Free interest rate		2.79% to 3.08%			2.79% to 3.08%
Forfeiture rate		0.00	%		0.00	%
Expected dividend rate		0.00	%		0.00	%

The expected term is estimated as the numbers needed for the calculation will not be available until the underlying common stock is quoted on an OTC market for a sufficient amount of time to obtain historical patterns and volatility.

The following table summarizes information about all of the stock options outstanding under the 2016 Plan at December 31, 2018 and June 30, 2018:

Employees/Consultants	Shares			Wtd. Avg.
Outstanding at June 30, 2017		6,627,720		$	0.20
Granted		5,500,000		$	0.20
Exercised		-		$	-
Cancelled		(490,943	)	$	0.20
Outstanding at June 30, 2018		11,636,777		$	0.20
Granted		-		$	-
Exercised		-		$	-
Cancelled		(589,132	)	$	0.20
Outstanding at December 31, 2018		11,047,645		$	0.20

At December 31, 2018, the Company has issued options pursuant to six different stock option plans, the most recent being the 2016 Plan. The previous five plans through and including the 2012 Non-Statutory Plan have a remaining total of options vested and exercisable to purchase 13 shares at exercise prices from a high of $13,500 to a low of $350 per share. The tables below summarize information about these five plans:

Employees/Consultants	Shares			Wtd. Avg.
Outstanding at June 30, 2017		65		$	12,070
Granted		-		$	-
Exercised		-		$	-
Cancelled		(52	)	$	14,770
Outstanding at June 30, 2018		13		$	1,210
Granted		-		$	-
Exercised		-		$	-
Cancelled		(0.31	)	$	6,083
Outstanding at December 31, 2018		13		$	976

Vested & Exercisable Stock Options	December 31, 2018		June 30, 2018
Employee 2016 Equity Plan		-		-
Director 2016 Equity Plan		-		-
Employee Other Plans		13		13
Directors and Consultants Other Plans		-		-
Total		13		13

The Company’s common stock, symbol IMDS, was quoted on OTCmarkets.com Pink until September 25, 2014 at which time IDSI’s registration was revoked by the Securities and Exchange Commission (SEC) for failure to timely file its Quarterly and Annual Reports. The last quoted price was $0.1. Because the Company was de-registered and OTC markets did not provide a quote for IMDS, there is no public market for the Company’s shares. Given the exercise prices adjusted for the reverse split, it is highly unlikely that any employee holding pre-2016 Plan options will exercise them. The Company has sufficient authorized shares available for all outstanding option; however, if exercised, the shares will be issued with a restrictive legend because the Company was not an SEC reporting company until October 2018. Further, given its recent return to SEC reporting status, the Company is unable to file an S-8 Registration Statement to register shares issued because of option exercise pursuant to various stock option agreements.

XML

Commitments and Contingencies

6 Months Ended

Dec. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

(15) COMMITMENTS AND CONTINGENCIES

The Company previously carried $3,000,000 in product liability insurance to cover both clinical sites and sales. As part of its cost savings initiatives, the Company cancelled the policy as it had not had any adverse experiences after conducting more than 25,000 patient scans worldwide. The Company is now self-insuring the risk of product liability. The Company is about to begin a new series of clinical trials in the U.S. and also to engage the services of a medical device contract manufacturer. Each hospital will have their own requirements regarding product liability insurance and the Company will obtain such insurance when requested. The medical device manufacturer has stated in their contract that they will require $2,000,000 product liability insurance before commencing the manufacture of CTLM® systems.

From May 2010 to June 2012, claims were made by the IRS for payment of the Company’s accrued payroll taxes, interest and penalties, which as of June 30, 2012 was $1,489,640. The Company engaged tax counsel to handle this matter and intends to fully satisfy its payroll tax obligations. On August 4, 2014, Viable purchased 250 shares of convertible preferred stock for $2,500,000, which gave them a 78.9% voting and economic interest in the Company’s capital stock representing a change in control of the Company. New management’s tax counsel negotiated a new Installment Agreement which stipulated a lump sum payment of $250,000, which was paid on September 4, 2014 and monthly installment payments of $20,000 beginning in September 2014 due on the 18^th of each month until the balance of payroll taxes, interest and penalties are paid in full.

During fiscal 2018, as part of new management’s restructuring plan, the Company received funds from an accredited investor to pay off the payroll tax portion of the amount owed to the IRS. The Company engaged tax counsel to manage the settlement and payment. On June 27, 2018, the IRS provided counsel with a payoff calculation table indicating that the balance of taxes due was $381,224. On June 29, 2018, Viable International Investments LLC provided a bank check in that amount to counsel and they sent the check to the IRS with a letter requesting abatement of penalties and interest totaling $314,019. The IRS is considering the request.

The Company leases a commercial building from Isco Properties, LLC for its offices and warehouse in Fort Lauderdale, FL. The term of the lease was five years beginning February 2014 with a monthly base rent beginning at $6,360 and increasing at a rate of 3% per year. The total rent commitment for the five years was $405,031 of which $397,886 was paid through December 31, 2018, leaving a balance due of $7,145. Total rent expense for operating leases for offices and manufacturing facilities amounted to $42,868 and $41,698 for the six months ended December 31, 2018 and 2017, respectively. On October 31, 2018, the Company extended the lease for two years from February 1, 2019 to January 31, 2021. The monthly base rent is $7,150 for the 1^st year and $7,350 for the 2^nd year. The rent commitment including sales tax for the two years is $184,092.

XML

Subsequent Events

6 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

(16) SUBSEQUENT EVENTS

On January 1, 2019, the Board granted options to purchase 2,040,000 shares all with an exercise price of $0.20 per share to five consultants. These options were valued using the Black-Scholes model but based on exercise price and fair value being the same as described in note (14). Under this assumption, the options have zero value.

On January 8, 2019, the Company entered into a lease agreement with Central Fla Linc-Merc Inc for a 2019 Lincoln Navigator SUV. The term of the lease is 3 years beginning January 8, 2019 with a monthly lease payment of $1,203.83 due on the 7th day of each month. The total lease commitment including sales tax for the 3 years is $43,337.88.

On January 22, 2019, the Company issued 98,039 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement dated 12/21/18 for $50,000. The price per share was approximately $0.51 per share.

On January 22, 2019, the Company issued 98,039 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $50,000. The price per share was approximately $0.51 per share.

On January 22, 2019, the Company issued 196,078 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $100,000. The price per share was approximately $0.51 per share.

On January 22, 2019, the Company issued 313,725 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $160,000. The price per share was approximately $0.51 per share.

As of January 27, 2019, Underwriter's Laboratory has not renewed our CE mark as we were not able to provide sufficient evidence in time to meet the deadline. We are working with UL to provide the evidence required to renew the CE Mark. Until the CE Mark is renewed, we will not be able to sell CTLM devices in Europe. 

On January 29, 2019, the Company issued 137,255 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $70,000. The price per share was approximately $0.51 per share.

On January 29, 2019, the Company issued 156,863 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $80,000. The price per share was approximately $0.51 per share.

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of presentation and use of estimates

(a) Basis of presentation and use of estimates

The financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America ("U.S. GAAP"). The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates and assumptions also include the valuations of certain financial instruments, stock-based compensation, deferred tax assets, the outcome of litigation and tax matters, and other matters that affect the statements of financial condition and related disclosures. Actual results could differ materially from these estimates.

These unaudited financial statements should be read in conjunction with the Company's audited financial statements for the year ended June 30, 2018, contained in our General Form for Registration of Securities of Form 10 as filed with the Securities and Exchange Commission (the "Commission") on August 28, 2018, as amended on October 5, 2018, and as amended on November 14, 2018. The results of operations for the six months ended December 31, 2018, are not necessarily indicative of results to be expected for any other interim period or the fiscal year ending June 30, 2019.

Revenue recognition

(b) Revenue recognition

As of July 1, 2018, the Company adopted Revenue from Contracts with Customers (Topic 606) ("ASC 606"). The Company sells medical imaging products, parts, and services where permitted to independent distributors and in certain unrepresented territories directly to end-users. The Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Product sales occur once control is transferred upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of consideration the Company receives and revenue the Company recognizes varies with changes in customer incentives the Company offers to its customers and their customers. Any discounts, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue. Sales taxes and other similar taxes are excluded from revenue.

Allowance for doubtful accounts

(c) Allowance for doubtful accounts

In the event that management determines that a receivable becomes uncollectible, or events or circumstances change, which result in a temporary cessation of payments from the distributor, we will make our best estimate of probable or potential losses in our accounts receivable balance using the allowance method for each quarterly period. Management will review the receivables at the end of each fiscal year and the appropriate allowance will be made based on current available evidence and historical experience.

Our allowance for doubtful accounts was $-0- as of December 31, 2018 and June 30, 2018.

Cash and cash equivalents

(d) Cash and cash equivalents

Holdings of highly liquid investments with original maturities of three months or less and investment in money market funds are considered to be cash equivalents by the Company. There were no cash equivalents at December 31, 2018 and June 30, 2018.

Concentration of Risk

(e) Concentration of Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.

The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company's cash accounts may exceed the Federal Deposit Insurance Corporation limit of $250,000. At December 31, 2018 and June 30, 2018, the Company had $0 and $0 in excess of the federally insured limit.

For the six months ended December 31, 2018 and December 31, 2017, the Company had the following 10 percent or greater concentrations of revenue with its customers:

	December 31, 2018			December 31, 2017
Xi'an IDI Laser Image		100	%		15	%
Trifoil		0	%		80	%
All other		0	%		5	%
Total		100	%		100	%

Inventory

(f) Inventory

Inventories, consisting principally of raw materials, work-in-process (including completed units under testing), finished goods and units placed on consignment, are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Raw materials consist of purchased parts, components and supplies. Work-in-process includes completed units undergoing final inspection and testing. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of slow moving or obsolete inventory. The Company maintains a reserve for obsolete inventory and generally makes inventory value adjustments against the reserve.

Property and equipment

(g) Property and equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using straight-line methods over the estimated useful lives of the related assets. Expenditures for renewals and betterments which increase the estimated useful life or capacity of the asset are capitalized; expenditures for repairs and maintenance are expensed when incurred.

Research and development

(h) Research and development

Research and development expenses consist principally of expenditures for equipment and outside third-party consultants, raw materials which are used in testing and the development of the Company's CTLM® device or other products and product software. The non-payroll related expenses include testing at outside laboratories, parts associated with the design of initial components and tooling costs, and other costs which do not remain with the developed CTLM® device.

Net loss per share

(i) Net loss per share

The Company relies on the guidance provided by ASC 260, ("Earnings per Share"), which requires the reporting of both basic and diluted earnings per share. Basic net loss per share is determined by dividing loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted into common stock, as long as the effect of their inclusion is not anti-dilutive.

The Company had 4,811,610 and 4,811,610 options vested as of December 31, 2018 and June 30, 2018, respectively.

Stock-based compensation

(j) Stock-based compensation

The Company relies on the guidance provided by ASC 718, ("Share Based Payments"). ASC 718 requires companies to expense the value of employee stock options and similar awards and applies to all outstanding and vested stock-based awards.

In computing the impact, the fair value of each option is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk-free interest rate; volatility; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company's stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company's forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. If the Company's actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what we have recorded in the current period. For the six months ended December 31, 2018 and 2017, no stock options were granted to employees and consultants. Stock options are being expensed pursuant to ASC 718.

The fair value concepts were not changed significantly in ASC 718; however, in adopting this Standard, companies were given the option to choose among alternative valuation models and amortization assumptions. We elected to continue to use the Black-Scholes option pricing model and expense the options as compensation over the requisite service period of the grant. We will reconsider use of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated using this model. See (14) Stock Options.

Long-lived assets

(k) Long-lived assets

The Company relies on the guidance provided by ASC 360 ("Property, Plant & Equipment"). ASC 360 requires companies to write down to estimated fair value long-lived assets that are impaired. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In performing the review of recoverability, the Company estimates the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized.

The Company has determined that no impairment losses need to be recognized through the six months ended December 31, 2018 and 2017.

Income taxes

(l) Income taxes

The Company accounts for income taxes pursuant to the provisions of ASC 740-10, "Accounting for Income Taxes," which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.

Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax positions.

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. As of the date these financials were available to be issued, tax years ended June 30, 2015-2018 are still potentially subject to audit by the taxing authorities.

Warranty reserve

(m) Warranty reserve

The Company warrants all products and parts supplied for a period of 12 months from the date of installation or 15 months from the date the products was/were shipped from IDSI, whichever occurs first. The table below reflects the warranty reserve established for the six months ended December 31, 2018 and the fiscal year ended June 30, 2018. Although the Company tests its product in accordance with its quality programs and processes, its warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Based on the Company's experience, the warranty reserve was estimated based on the replacement cost of the laser and certain electronic parts. Should actual product failure rates or service costs differ from the Company's estimates, which are based on limited historical data, where applicable, revisions to the estimated warranty liability would be required. The following warranty reserve balances are included in accounts payable and accrued expenses.

	December 31, 2018		June 30, 2018
Warranty reserve	$	0	$	6,411

Impact of recently issued accounting pronouncements

(n) Impact of recently issued accounting pronouncements

In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02"). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its financial statements.

In June 2018, the FASB issued ASU No. 2018-07, "Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting." ASU 2018-07 aligns accounting for share-based payments issued to nonemployees to that of employees under the existing guidance of Topic 718, with certain exceptions. This update supersedes previous guidance for equity-based payments to nonemployees under Subtopic 505-50, "Equity – Equity-based Payments to Nonemployees." It is effective for annual reporting periods beginning after December 15, 2018. The Company is currently evaluating the impact the adoption of this new standard will have on its financial statements.

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.

Fair Value of Financial Instruments

(o) Fair Value of Financial Instruments

The carrying values of cash and cash equivalents, receivables, accounts payable, short-term debt and accrued liabilities approximated their fair values due to the short maturity of these instruments. After a review of our accounts receivable, the Company has not recorded an allowance for doubtful accounts. The fair value of the Company's debt obligations is estimated based on the quoted market prices for the same or similar issues or on current rates offered to the Company for debt of the same remaining maturities. At December 31, 2018 and June 30, 2018, the aggregate fair value of the Company's debt obligations approximated its carrying value. The Company relies upon the guidance of ASC 820 ("Fair Value Measurements and Disclosures"). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly, transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:

Level 1 - Quoted prices in active markets for identical assets or liabilities

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

XML

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of concentrations percent

	December 31, 2018			December 31, 2017
Xi'an IDI Laser Image		100	%		15	%
Trifoil		0	%		80	%
All other		0	%		5	%
Total		100	%		100	%

Schedule of warranty reserve balances

	December 31, 2018		June 30, 2018
Warranty reserve	$	0	$	6,411

XML

Revenue (Tables)

6 Months Ended

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Schedule of net sales by reporting segment

	For the six months ended
	December 31,		December 31,
	2018		2017
Sales-parts	$	149,066	$	15,158
Royalty Revenue		-		83,506
Service revenue		-		5,375
Net sales	$	149,066	$	104,039

XML

Inventories (Tables)

6 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Schedule of inventories

	December 31,			June 30,
	2018			2018
Raw materials consisting of purchased parts, components and supplies	$	386,588		$	415,262
Work-in process including units undergoing final inspection and testing		52,500			52,500
Finished goods		15,000			15,000
Total Inventory	$	454,088		$	482,762
Inventory Reserve		(454,088	)		(482,762	)
Net Inventory	$	-		$	-

XML

Property and Equipment (Tables)

6 Months Ended

Dec. 31, 2018

Property, Plant and Equipment [Abstract]

Schedule of property and equipment, less accumulated depreciation

	December 31, 2018			June 30, 2018			Useful life
Furniture and Fixtures	$	261,011		$	261,011		5 years
Computers and Equipment		370,704			370,704		5 years
Third Party Software		10,291			10,291		5 years
Clinical Equipment		15,000			15,000		5 years
Total Property & Equipment	$	657,006		$	657,006
Less: accumulated depreciation		(633,723	)		(629,828	)
Total Property & Equipment - Net	$	23,283		$	27,178

XML

Short-Term Debt-Related Parties (Tables)

6 Months Ended

Dec. 31, 2018

Debt Disclosure [Abstract]

Schedule of outstanding note balance

Noteholder	Interest Rate			Maturity Date	December 31, 2018		June 30, 2018
Related parties debt:
Erhfort, LLC		15	%	8/8/2019	$	100,000	$	-0-
Erhfort, LLC		15	%	9/12/2019		100,000		-0-
Erhfort, LLC		15	%	10/24/2019		50,000		-0-
Erhfort, LLC		15	%	11/15/2019		50,000		-0-
Qing Wang		15	%	9/21/2019		100,000		-0-
Total Related Party Debt					$	400,000	$	-0-

XML

Convertible Preferred Stock (Tables)

6 Months Ended

Dec. 31, 2018

Equity [Abstract]

Schedule of preferred stock

Security	Date Issued	No. of Shares	Amount		Date of Conversion	No. of Shares Converted	Amount Converted		Balance 09/30/2018
Series M Cv Pfd	8/1/2014	250	$	2,500,000	4/18/2017	6	$	60,000
					11/21/2017	3		30,000
					8/7/2018	241		2,410,000	$	-0-
Series M Cv Pfd	8/31/2015	200		2,000,000	8/7/2018	200		2,000,000		-0-
Series M Cv Pfd	4/22/2016	150		1,500,000	8/7/2018	150		1,500,000		-0-
Total		600	$	6,000,000			$	6,000,000	$	-0-
Accrued Dividends										-0-
									$	-0-
Series L Cv Pfd	2/10/2010	35	$	350,000	1/6/2011	15	$	150,000	$	200,000
Accrued Dividends										170,988
									$	370,988

XML

Stock Options (Tables)

6 Months Ended

Dec. 31, 2018

Schedule of stock option grants fair value of each option

	As of December 31, 2018			As of June 30, 2018
Expected volatility		0.00	%		0.00	%
Expected term		3 Years			3 Years
Risk-Free interest rate		2.79% to 3.08%			2.79% to 3.08%
Forfeiture rate		0.00	%		0.00	%
Expected dividend rate		0.00	%		0.00	%

Schedule of vested & exercisable stock options

Vested & Exercisable Stock Options	December 31, 2018		June 30, 2018
Employee 2016 Equity Plan		-		-
Director 2016 Equity Plan		-		-
Employee Other Plans		13		13
Directors and Consultants Other Plans		-		-
Total		13		13

2016 Plan [Member]

Schedule of stock options outstanding activity

Employees/Consultants	Shares			Wtd. Avg.
Outstanding at June 30, 2017		6,627,720		$	0.20
Granted		5,500,000		$	0.20
Exercised		-		$	-
Cancelled		(490,943	)	$	0.20
Outstanding at June 30, 2018		11,636,777		$	0.20
Granted		-		$	-
Exercised		-		$	-
Cancelled		(589,132	)	$	0.20
Outstanding at December 31, 2018		11,047,645		$	0.20

2012 Non-Statutory Plan [Member]

Schedule of stock options outstanding activity

Employees/Consultants	Shares			Wtd. Avg.
Outstanding at June 30, 2017		65		$	12,070
Granted		-		$	-
Exercised		-		$	-
Cancelled		(52	)	$	14,770
Outstanding at June 30, 2018		13		$	1,210
Granted		-		$	-
Exercised		-		$	-
Cancelled		(0.31	)	$	6,083
Outstanding at December 31, 2018		13		$	976

XML

Going Concern and Management's Plans (Details) - USD ($)	3 Months Ended			6 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Going Concern and Management's Plans (Textual)
Accumulated deficit	$ (132,152,132)			$ (132,152,132)		$ (133,064,117)
Stockholders' deficit	(933,953)	$ (772,444)		(933,953)		$ (366,765)
Working capital deficiency	957,236			957,236
Net loss	$ (356,975)	$ (401,142)	$ (352,805)	(758,114)	$ (771,958)
Net cash used in operating activities				$ (855,635)	$ (665,787)

XML

Summary of Significant Accounting Policies (Details)	6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total concentration risk percentage	100.00%	100.00%
Xi'an IDI Laser Image [Member]
Total concentration risk percentage	100.00%	15.00%
Trifoil [Member]
Total concentration risk percentage	0.00%	80.00%
All other [Member]
Total concentration risk percentage	0.00%	5.00%

XML

Summary of Significant Accounting Policies (Details1) - USD ($)	Dec. 31, 2018	Jun. 30, 2018
Accounting Policies [Abstract]
Warranty reserve	$ 0	$ 6,411

XML

Summary of Significant Accounting Policies (Details Textual) - USD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Summary of Significant Accounting Policies (Textual)
Allowance for doubtful accounts	$ 0		$ 0
Cash equivalents	0		0
Federal deposit insurance corporation limit	250,000
Excess of federally insured limit	$ 0		$ 0
Concentrations of revenue with customers	10 percent or greater concentrations of revenue with its customers.	10 percent or greater concentrations of revenue with its customers.
Options vested	4,811,610		4,811,610

XML

Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Net sales	$ 11,278	$ 83,506	$ 149,066	$ 104,039
Sales-parts [Member]
Net sales			149,066	15,158
Royalty Revenue [Member]
Net sales				83,506
Service revenue [Member]
Net sales				$ 5,375

XML

Due from Related Party (Details)	1 Months Ended	6 Months Ended
	Mar. 22, 2018 Number	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Jun. 30, 2018 USD ($)
Due from Related Party (Textual)
Receivables from related parties		$ 134,018		$ 34,853
Xi'an [Member]
Due from Related Party (Textual)
Number of agreements | Number	2
Term of contract	20 years
Percentage of revenue for product sales	25.00%
Sales from related party		149,066	$ 15,158
Receivables from related parties		$ 134,018		$ 34,853

XML

Royalty Receivable (Details)	6 Months Ended
	Dec. 31, 2018 USD ($)
Royalty Receivable (Textual)
Royalty income

XML

Inventories (Details) - USD ($)	Dec. 31, 2018	Jun. 30, 2018
Inventory Disclosure [Abstract]
Raw materials consisting of purchased parts, components and supplies	$ 386,588	$ 415,262
Work-in process including units undergoing final inspection and testing	52,500	52,500
Finished goods	15,000	15,000
Total Inventory	454,088	482,762
Inventory Reserve	(454,088)	(482,762)
Net Inventory

XML

Inventories (Details Textual)	Dec. 31, 2018 USD ($)
Inventories (Textual)
Purchased inventory	$ 65,000

XML

Property and Equipment (Details) - USD ($)	6 Months Ended
	Dec. 31, 2018	Jun. 30, 2018
Total Property & Equipment	$ 657,006	$ 657,006
Less: accumulated depreciation	(633,723)	(629,828)
Total Property & Equipment - Net	23,285	27,178
Furniture and Fixtures [Member]
Total Property & Equipment	$ 261,011	261,011
Useful life	5 years
Computers and Equipment [Member]
Total Property & Equipment	$ 370,704	370,704
Useful life	5 years
Third Party Software [Member]
Total Property & Equipment	$ 10,291	10,291
Useful life	5 years
Clinical Equipment [Member]
Total Property & Equipment	$ 15,000	$ 15,000
Useful life	5 years

XML

Property and Equipment (Details Textual) - USD ($)	6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property and Equipment (Textual)
Depreciation expense	$ 3,893	$ 3,893

XML

Accounts Payable and Accrued Expenses (Details) - USD ($)	Dec. 31, 2018	Jun. 30, 2018
Accounts Payable and Accrued Expenses (Textual)
Accounts payable and accrued expenses	$ 56,330	$ 69,756
Accounts payable	25,065	2,308
Warranty reserve	0	6,411
Other accrued expenses	$ 30,265	61,037
Write-offs of accounts payable and accrued expenses		44,611
Restricted Common Shares [Member]
Accounts Payable and Accrued Expenses (Textual)
Accounts payable		190,000
Accrued salaries		$ 20,000

XML

Accrued Payroll Taxes and Penalties (Details) - USD ($)	Dec. 31, 2018	Jun. 30, 2018	Jun. 27, 2018
Accrued Payroll Taxes and Penalties (Textual)
Accrued payroll taxes and penalties	$ 314,020	$ 314,019
Balance of taxes due			$ 381,224
Amount of interest and penalty	314,018
Remaining interest and penalties	$ 314,018

XML

Short-Term Debt-Related Parties (Details) - USD ($)	6 Months Ended
	Dec. 31, 2018	Jun. 30, 2018
Related parties debt:
Total Related Party Debt	$ 400,000
Erhfort, LLC [Member]
Related parties debt:
Noteholder	Erhfort, LLC
Interest Rate	15.00%
Maturity Date	Aug. 08, 2019
Total Related Party Debt	$ 100,000	0
Erhfort, LLC [Member]
Related parties debt:
Noteholder	Erhfort, LLC
Interest Rate	15.00%
Maturity Date	Sep. 12, 2019
Total Related Party Debt	$ 100,000	0
Erhfort, LLC [Member]
Related parties debt:
Noteholder	Erhfort, LLC
Interest Rate	15.00%
Maturity Date	Oct. 24, 2019
Total Related Party Debt	$ 50,000	0
Erhfort, LLC [Member]
Related parties debt:
Noteholder	Erhfort, LLC
Interest Rate	15.00%
Maturity Date	Nov. 15, 2019
Total Related Party Debt	$ 50,000	0
Qing Wang [Member]
Related parties debt:
Noteholder	Qing Wang
Interest Rate	15.00%
Maturity Date	Sep. 21, 2019
Total Related Party Debt	$ 100,000	$ 0

XML

Short-Term Debt-Related Parties (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 27, 2018	Jun. 30, 2018
Short-Term Debt-Related Parties (Textual)
Issued restricted common shares to settlement of debt		$ 200,000
Issued restricted common shares		1,000,000
Redwood Management [Member]
Short-Term Debt-Related Parties (Textual)
Paid for settlement of debt	$ 63,500
Late payment fee	$ 1,000

XML

Convertible Preferred Stock (Details) - USD ($)	6 Months Ended
	Dec. 31, 2018	Jun. 30, 2018
Balance	$ 370,988	$ 361,914
Series M Cv Pfd [Member]
No. of shares	600
Amount of preferred shares	$ 6,000,000
Amount Converted	6,000,000
Accrued Dividends	0
Balance	$ 0
Series M Cv Pfd [Member] | 8/1/2014 One [Member]
Date of Conversion.	Nov. 21, 2017
No. of Shares Converted	3
Amount Converted	$ 30,000
Series M Cv Pfd [Member] | 8/1/2014 Two [Member]
Date of Conversion.	Aug. 07, 2018
No. of Shares Converted	241
Amount Converted	$ 2,410,000
Balance	$ 0
Series M Cv Pfd [Member] | 8/31/2015 [Member]
No. of shares	200
Amount of preferred shares	$ 2,000,000
Date of Conversion.	Aug. 07, 2018
No. of Shares Converted	200
Amount Converted	$ 2,000,000
Balance	$ 0
Series M Cv Pfd [Member] | 4/22/2016 [Member]
No. of shares	150
Amount of preferred shares	$ 1,500,000
Date of Conversion.	Aug. 07, 2018
No. of Shares Converted	150
Amount Converted	$ 1,500,000
Balance	$ 0
Series M Cv Pfd [Member] | 8/1/2014 [Member]
No. of shares	250
Amount of preferred shares	$ 2,500,000
Date of Conversion.	Apr. 18, 2017
No. of Shares Converted	6
Amount Converted	$ 60,000
Series L Cv Pfd [Member]
Accrued Dividends	$ 170,988
Series L Cv Pfd [Member] | 2/10/2010 [Member]
No. of shares	35
Amount of preferred shares	$ 350,000
Date of Conversion.	Jan. 06, 2011
No. of Shares Converted	15
Amount Converted	$ 150,000
Balance	$ 2,000,000

XML

Convertible Preferred Stock (Details Textual)				1 Months Ended
	Aug. 07, 2018 shares	Aug. 04, 2014	Jan. 06, 2011 USD ($) shares	Nov. 21, 2017 USD ($) Number shares	Apr. 18, 2017 USD ($) Number shares	Apr. 22, 2016 USD ($) shares	Aug. 31, 2015 USD ($) shares	Dec. 31, 2018 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2015 USD ($)	Jun. 27, 2014 USD ($) shares	Mar. 31, 2010 USD ($) shares
Redemption value								$ 170,988	$ 161,914
Current liability								370,988	361,914
Remaining principal value of cumulative dividend								200,000
Series M Convertible Preferred Stock [Member]
Convertible preferred stock | shares	591					150	200				250
Original purchase price										$ 10,000
Annual rate										9.00%
Redemption value								0	$ 1,679,173
Current liability								$ 0
Non-refundable deposit											$ 100,000
Preferred stock voting rights		At the first closing, $2,400,000 was paid by Viable to purchase 250 shares of convertible preferred stock which provided a 78.9% voting and economic interest in the Company's capital stock representing a change in control of the Company.
Issuance of convertible preferred stock				$ 30,000	$ 60,000	$ 1,500,000	$ 2,000,000
Restricted common shares | shares	87,044,089			441,848	883,696
Number of investors | Number				3	3
Restricted common shares retained | shares				49,691	10,909
Series M Convertible Preferred Stock [Member] | Investor [Member]
Restricted common shares | shares				392,157	872,787
Series L Convertible Preferred Stock [Member]
Converted short term promissory note												$ 350,000
Convertible preferred stock | shares			15									35
Original purchase price												$ 10,000
Annual rate												9.00%
Conversion of preferred stock to common stock | shares												474
Conversion of preferred stock, description			The private investor held 20 shares representing a principal value of $200,000. The remaining principal value of $200,000 is presented on the balance sheet as a current liability since it is mandatorily redeemable.
Principal value			$ 150,000

XML

Common Stock (Details) - USD ($)					1 Months Ended					6 Months Ended	12 Months Ended
	Aug. 07, 2018	Jul. 12, 2018	Jan. 10, 2018	Aug. 15, 2016	Dec. 27, 2018	Jun. 28, 2018	May 20, 2018	Apr. 23, 2018	Nov. 21, 2017	Dec. 31, 2018	Jun. 30, 2018
Common Stock (Textual)
Description of reverse stock split		The majority shareholder of the Company, Viable International Investments, LLC delivered a written request to effect a one-for-1000 reverse stock split in the form of a Written Consent of the Majority Shareholder of Imaging Diagnostic Systems, Inc. The Board of Directors of the Corporation believed it to be in the best interest of the Corporation and recommended that the stockholders approve a one-for-1000 reverse stock split of the Corporation's issued and outstanding shares of Common Stock and a decrease in the amount of shares of Common Stock authorized to be issued from 40,000,000,000 shares to 500,000,000 shares.
Common Stock, par value
Common Stock, shares authorized										500,000,000	500,000,000
Preferred Stock, par value
Preferred Stock, shares authorized										2,000,000	2,000,000
Issued total shares of common stock										87,338,207	11,822,730
Description of convertible terms				An accredited investor, loaned the Company the sum of $750,000 pursuant to a convertible promissory note. Pursuant to a debt to equity agreement dated June 28, 2018, the investor converted the principal of $750,000 and interest of $213,750 into 1,889,706 shares of restricted common stock. The conversion price was $0.51 per share, based on the last cash sale price of the Company's common stock.
Subscription Agreement [Member]
Common Stock (Textual)
Shares of restricted common stock					98,039
Values of restricted common stock					$ 50,000
Share price per share					$ 0.51
Subscription Agreement One [Member]
Common Stock (Textual)
Shares of restricted common stock					98,039
Values of restricted common stock					$ 50,000
Share price per share					$ 0.51
Subscription Agreement Two [Member]
Common Stock (Textual)
Shares of restricted common stock					98,039
Values of restricted common stock					$ 50,000
Share price per share					$ 0.51
Restricted Common Shares [Member] | Non-Affiliated Accredited Investor [Member]
Common Stock (Textual)
Issued shares pursuant to subscription agreement								588,235	588,235
Issued value pursuant to subscription agreement								$ 300,000	$ 300,000
Price per share								$ 0.51	$ 0.51
Restricted Common Shares [Member] | Accredited Investor [Member]
Common Stock (Textual)
Issued shares as settlement of company debt						1,372,549	392,157
Issued value as settlement of company debt						$ 700,000	$ 200,000
Price per share						$ 0.51	$ 0.51
Issued date						Jun. 30, 2018	Jun. 30, 2018
Restricted Common Shares [Member] | Settlement of Company Debt [Member]
Common Stock (Textual)
Issued shares as settlement of company debt			1,000,000			3,000,000		1,500,000
Issued value as settlement of company debt			$ 200,000			$ 600,000		$ 300,000
Price per share			$ 0.20			$ 0.20		$ 0.20
Restricted Common Shares [Member] | Settlement of Accrued Salaries [Member]
Common Stock (Textual)
Issued shares as settlement of accounts payable and accrued expenses			100,000
Issued value as settlement of accounts payable and accrued expenses			$ 20,000
Price per share			$ 0.20
Restricted Common Shares [Member] | Settlement of Accounts Payable [Member]
Common Stock (Textual)
Issued shares as settlement of accounts payable and accrued expenses			240,000					710,000
Issued value as settlement of accounts payable and accrued expenses			$ 48,000					$ 142,000
Price per share			$ 0.20					$ 0.20
Series M Convertible Preferred Stock [Member]
Common Stock (Textual)
Convert shares of convertible preferred stock	591								3
Convert value of convertible preferred stock	$ 5,910,000								$ 30,000
Convertible preferred stock shares converted into restricted common stock	87,044,089								441,848

XML

Stock Options (Details)	6 Months Ended	12 Months Ended
	Dec. 31, 2018	Jun. 30, 2018
Expected volatility	0.00%	0.00%
Expected term	3 years	3 years
Forfeiture rate	0.00%	0.00%
Expected dividend rate	0.00%	0.00%
Minimum [Member]
Risk-Free interest rate	2.79%	2.79%
Maximum [Member]
Risk-Free interest rate	3.08%	3.08%

XML

Stock Options (Details 1) - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2018	Jun. 30, 2018
2016 Plan [Member]
Shares
Beginning Outstanding	11,636,777	6,627,720
Granted		5,500,000
Exercised
Cancelled	(589,132)	(490,943)
Ending Outstanding	11,047,645	11,636,777
Wtd. Avg.
Beginning Outstanding	$ 0.20	$ 0.20
Granted		0.20
Exercised
Cancelled	0.20	0.20
Ending Outstanding	$ 0.20	$ 0.20
2012 Non-Statutory Plan [Member]
Shares
Beginning Outstanding	13	65
Granted
Exercised
Cancelled	(0.31)	(52)
Ending Outstanding	13	13
Wtd. Avg.
Beginning Outstanding	$ 1,210	$ 12,070
Granted
Exercised
Cancelled	6,083	14,770
Ending Outstanding	$ 976	$ 1,210

XML

Stock Options (Details 2) - shares	Dec. 31, 2018	Jun. 30, 2018
Vested & Exercisable Stock Options
Total	13	13
Employee 2016 Equity Plan [Member]
Vested & Exercisable Stock Options
Total
Director 2016 Equity Plan [Member]
Vested & Exercisable Stock Options
Total
Employee Other Plans [Member]
Vested & Exercisable Stock Options
Total	13	13
Directors and Consultants Other Plans [Member]
Vested & Exercisable Stock Options
Total

XML

Stock Options (Details Textual) - $ / shares				6 Months Ended
	May 01, 2018	Jan. 03, 2018	Jan. 01, 2017	Dec. 31, 2018	Sep. 25, 2014
Stock Options (Textual)
Granted options to purchase shares			7,364,136
Purchase exercise price			$ 0.20
Stock options, description				The previous five plans through and including the 2012 Non-Statutory Plan have a remaining total of options vested and exercisable to purchase 13 shares at exercise prices from a high of $13,500 to a low of $350 per share.
Quoted price					$ 0.1
Nine Employees [Member]
Stock Options (Textual)
Granted options to purchase shares			5,498,555
Six Consultants [Member]
Stock Options (Textual)
Granted options to purchase shares			1,865,581
Four Consultants [Member]
Stock Options (Textual)
Granted options to purchase shares		5,000,000
Purchase exercise price		$ 0.20
Additional Consultant [Member]
Stock Options (Textual)
Granted options to purchase shares	500,000
Purchase exercise price	$ 0.20

XML

Commitments and Contingencies (Details)		1 Months Ended		6 Months Ended
	Aug. 04, 2014 USD ($) shares	Oct. 31, 2018	Feb. 28, 2014	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Jun. 29, 2018 USD ($)	Jun. 27, 2018 USD ($)	Sep. 04, 2014 USD ($)	Jun. 30, 2012 USD ($)
Product liability insurance				$ 3,000,000
Number of patents scans conducted worldwide				25,000
Accrued payroll taxes, interest and penalties									$ 1,489,640
Purchase of convertible preferred stock | shares	250
Convertible preferred stock value	$ 2,500,000
Voting and economic interest percentage	78.90%
Lump sum payment								$ 250,000
Monthly installment payments								$ 20,000
Balance of taxes due							$ 381,224
Penalties and interest totaling						$ 314,019
Operating leasing, description		The Company extended the lease for two years from February 1, 2019 to January 31, 2021. The monthly base rent is $7,150 for the 1st year and $7,350 for the 2nd year. The rent commitment including sales tax for the two years is $184,092.	The term of the lease was five years beginning February 2014 with a monthly base rent beginning at $6,360 and increasing at a rate of 3% per year. The total rent commitment for the five years was $405,031 of which $397,886 was paid through December 31, 2018, leaving a balance due of $7,145.
Rent expense for operating leases				$ 42,868	$ 41,698
CTLM® systems [Member]
Product liability insurance				$ 2,000,000

XML

Subsequent Events (Details) - USD ($)				1 Months Ended
	Jan. 08, 2019	Jan. 01, 2019	Jan. 01, 2017	Jan. 29, 2019	Jan. 22, 2019
Subsequent Events (Textual)
Granted options to purchase shares			7,364,136
Purchase exercise price			$ 0.20
Subsequent Event [Member]
Subsequent Events (Textual)
Lease description	The Company entered into a lease agreement with Central Fla Linc-Merc Inc for a 2019 Lincoln Navigator SUV. The term of the lease is 3 years beginning January 8, 2019 with a monthly lease payment of $1,203.83 due on the 7th day of each month. The total lease commitment including sales tax for the 3 years is $43,337.88.
Granted options to purchase shares		2,040,000
Purchase exercise price		$ 0.20
Subsequent Event [Member] | Subscription Agreement [Member]
Subsequent Events (Textual)
Shares of restricted common stock				137,255	98,039
Values of restricted common stock				$ 70,000	$ 50,000
Share price per share				$ 0.51	$ 0.51
Subsequent Event [Member] | Subscription Agreement One [Member]
Subsequent Events (Textual)
Shares of restricted common stock				156,863	98,039
Values of restricted common stock				$ 80,000	$ 50,000
Share price per share				$ 0.51	$ 0.51
Subsequent Event [Member] | Subscription Agreement Two [Member]
Subsequent Events (Textual)
Shares of restricted common stock					196,078
Values of restricted common stock					$ 100,000
Share price per share					$ 0.51
Subsequent Event [Member] | Subscription Agreement Three [Member]
Subsequent Events (Textual)
Shares of restricted common stock					313,725
Values of restricted common stock					$ 160,000
Share price per share					$ 0.51